American Journal of Kidney Diseases
Volume 50, Issue 5 , Pages 774-781 , November 2007

The Relationship Between Dialysis Performance Measures: Adequacy and Anemia Management

  • Yonatan S. Spolter, BS

      Affiliations

    • Department of Medicine, University of Maryland School of Medicine, Baltimore, MD
    • ,
  • Stephen L. Seliger, MD, MS

      Affiliations

    • Department of Medicine, University of Maryland School of Medicine, Baltimore, MD
    • Department of Epidemiology and Preventive Medicine, University of Maryland School of Medicine, Baltimore, MD
    • ,
  • Min Zhan, PhD

      Affiliations

    • Department of Epidemiology and Preventive Medicine, University of Maryland School of Medicine, Baltimore, MD
    • ,
  • Van Doren Hsu, PharmD

      Affiliations

    • Pharmaceutical Research Computing, University of Maryland School of Pharmacy, Baltimore, MD.
    • ,
  • Lori D. Walker, BS

      Affiliations

    • Pharmaceutical Research Computing, University of Maryland School of Pharmacy, Baltimore, MD.
    • ,
  • Jeffrey C. Fink, MD, MS

      Affiliations

    • Department of Medicine, University of Maryland School of Medicine, Baltimore, MD
    • Department of Epidemiology and Preventive Medicine, University of Maryland School of Medicine, Baltimore, MD
    • Corresponding Author InformationAddress correspondence to Jeffrey C. Fink, MD, MS, Rm N3W143, 22 S Greene St, University of Maryland Medical System, Baltimore, MD 21201.

Received 15 January 2007 ,Accepted 7 August 2007.

References 

  1. McClellan WM, Soucie JM, Krisher J, Caruana R, Haley W, Farmer C. Improving the care of patients treated with hemodialysis: A report from the Health Care Financing Administration’s ESRD Core Indicators Project. Am J Kidney Dis. 1998;31:584–592
  2. Sugarman JR, Frederick PR, Frankenfield DL, Owen WF, McClellan WM. Dialysis Outcomes Quality Initiative Clinical Practice Guidelines: Developing clinical performance measures based on the Dialysis Outcomes Quality Initiative Clinical Practice Guidelines: Process, outcomes, and implications. Am J Kidney Dis. 2003;42:806–812
  3. Lacson E, Ofsthun N, Lazarus JM. Effect of variability in anemia management on hemoglobin outcomes in ESRD. Am J Kidney Dis. 2003;41:111–124
  4. Reddan DN, Frankenfield DL, Klassen PS, et al. Regional variability in anaemia management and haemoglobin in the US. Nephrol Dial Transplant. 2003;18:147–152
  5. Coyne DW, Delmez J, Spence G, Windus DW. Impaired delivery of hemodialysis prescriptions: An analysis of causes and an approach to evaluation. J Am Soc Nephrol. 1997;8:1315–1318
  6. Cotter DJ, Stefanik K, Zhang Y, Thamer M, Scharfstein D, Kaufman J. Hematocrit was not validated as a surrogate end point for survival among epoetin-treated hemodialysis patients. J Clin Epidemiol. 2004;57:1086–1095
  7. Lowrie EG, Lew NL. Death risk in hemodialysis patients: The predictive value of commonly measured variables and an evaluation of death rate differences between facilities. Am J Kidney Dis. 1990;15:458–482
  8. Eknoyan G, Beck GJ, Cheung AK, et al. Effect of dialysis dose and membrane flux in maintenance hemodialysis. N Engl J Med. 2002;347:2010–2019
  9. McClellan WM, Hodgkin E, Pastan S, McAdams L, Soucie JM. A randomized evaluation of two health care quality improvement program interventions to improve adequacy of hemodialysis care of ESRD patients: Feedback alone versus intensive intervention. J Am Soc Nephrol. 2004;15:754–760
  10. McClellan WM, Frankenfield DL, Frederick PR, et al. Can dialysis therapy be improved? (A report from the ESRD Core Indicators Project). Am J Kidney Dis. 1999;34:1075–1082
  11. Ifudu O, Feldman J, Friedman EA. The intensity of hemodialysis and the response to erythropoietin in patients with end-stage renal disease. N Engl J Med. 1996;334:420–425
  12. Ifudu O, Uribarri J, Rajwani I, et al. Adequacy of dialysis and differences in hematocrit among dialysis facilities. Am J Kidney Dis. 2000;36:1166–1174
  13. Forum of the ESRD Networks. Summary Report of the End Stage Renal Disease Networks’ Annual Report 2004. Baltimore, MD: Centers for Medicare & Medicaid Services; 2005;
  14. Magee L. R2 measures based on Wald and likelihood ratio joint significance tests. Am Stat. 1990;44:250–253
  15. Hanley JA, McNeill BJ. The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology. 1982;143:29–36
  16. Volkova N, Arab L. Evidence-based systematic literature review of hemoglobin/hematocrit and all-cause mortality in dialysis patients. Am J Kidney Dis. 2006;47:24–36
  17. Wolfe RA, Hulbert-Shearon TE, Ashby VB, Mahadevan S, Port FK. Improvements in dialysis patient mortality are associated with improvements in urea reduction ratio and hematocrit, 1999 to 2002. Am J Kidney Dis. 2005;45:127–135
  18. Szczech L, Klassen PS, Chua B, et al. Association between CMS’s Clinical Performance Measures project benchmark, profit structure, and mortality in dialysis units. Kidney Int. 2006;69:2094–2100
  19. Held PJ, Port FK, Wolfe RA, et al. The dose of hemodialysis and patient mortality. Kidney Int. 1996;50:550–556
  20. Hakim RM, Breyer J, Ismail N, Schulman G. Effects of dose of dialysis on morbidity and mortality. Am J Kidney Dis. 1994;23:661–669
  21. Ma JZ, Ebben J, Xia H, Collins AJ. Hematocrit level and associated mortality in hemodialysis patients. J Am Soc Nephrol. 1999;10:610–619
  22. Rocco MV, Frankenfield DL, Hopson SD, McClellan WM. Relationship between clinical performance measures and outcomes among patients receiving long-term hemodialysis. Ann Intern Med. 2006;145:512–519
  23. Merkin SS, Cavanaugh K, Longenecker JC, Fink NE, Levey AS, Powe NR. Agreement of self-reported comorbid conditions with medical and physician reports varied by disease among end-stage renal disease patients. J Clin Epidemiol. 2007;60:634–642

 Originally published online as doi:10.1053/j.ajkd.2007.08.006 on October 4, 2007.

PII: S0272-6386(07)01142-0

doi: 10.1053/j.ajkd.2007.08.006

American Journal of Kidney Diseases
Volume 50, Issue 5 , Pages 774-781 , November 2007

Article Tools

* Image Usage & Resolution